68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This prospective, single-center, open-label exploratory diagnostic study aims to evaluate the safety, feasibility, and diagnostic performance of the novel Sortilin-targeted PET tracer 68Ga-SorB in patients with solid tumors. Eligible participants with confirmed or suspected melanoma, hepatocellular carcinoma, lung cancer, pancreatic cancer, breast cancer, or ovarian cancer will undergo 68Ga-SorB PET/CT imaging. The imaging findings will be compared with standard-of-care 18F-FDG PET/CT, using pathology results and/or clinical follow-up as the reference standard. The primary objectives are to evaluate the safety and tolerability of 68Ga-SorB, assess imaging feasibility, and characterize tumor uptake using quantitative PET parameters, including SUVmax and tumor-to-background ratio (TBR). Secondary exploratory objectives include comparing lesion detection between 68Ga-SorB PET/CT and 18F-FDG PET/CT, assessing diagnostic sensitivity and specificity, evaluating imaging characteristics across different tumor types, and exploring the correlation between Sortilin expression and tracer uptake. This study will provide preliminary clinical evidence supporting the development of Sortilin-targeted molecular imaging and future theranostic applications.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18–75 lat
- •Potwierdzony lub podejrzewany nowotwór: czerniak, rak wątroby, płuc, piersi, trzustki lub jajników
- •Dobra ogólna kondycja zdolna do uczestnictwa w badaniu
- •Prawidłowa funkcja krwi, wątroby i nerek
- •Prawidłowe funkcje serca
- •Spodziewana długość życia co najmniej 12 tygodni
- •Co najmniej jeden wymierny guz
- •Kobieta w wieku rozrodczym musi stosować skuteczną antykoncepcję
✗ Disqualifies
- •Ciąża lub karmienie piersią
- •Poważne uszkodzenie serca, wątroby lub nerek
- •Niemożność poddania się badaniu obrazowemu lub ukończenia obserwacji
- •Inne warunki, które – zdaniem lekarza – czynią udział niestosownym
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- August 12, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Peking University Third Hospital
Beijing, China
Trial contact
Meixin Zhao
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/13/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.